Passage BIO, Inc.
Passage Bio, Inc. (Nasdaq Capital Market: PASG) is a clinical-stage genetic medicines company focused on developing one-time gene therapies to treat neurodegenerative diseases. The company's website is www.passagebio.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Passage BIO, Inc. does
In the company’s own words
Passage Bio, Inc. (Nasdaq Capital Market: PASG) is a clinical-stage genetic medicines company focused on developing one-time gene therapies to treat neurodegenerative diseases. The company's website is www.passagebio.com.
The company's lead clinical product candidate is PBFT02, a gene replacement therapy utilizing an adeno-associated virus serotype 1 capsid to deliver a functional granulin gene to the brain via intra cisterna magna administration. PBFT02 is being evaluated primarily for frontotemporal dementia caused by progranulin deficiency, or FTD-GRN, for which no disease-modifying therapies currently exist. The company estimates the prevalence of FTD-GRN in the United States and Europe at approximately 18,000 patients. Passage Bio is also exploring PBFT02's potential in additional neurodegenerative indications including FTD-C9orf72, amyotrophic lateral sclerosis, and Alzheimer's disease, where elevated progranulin levels may provide therapeutic benefit through reduction of pathologic TDP-43 accumulation.
The company is conducting the upliFT-D trial, an international multi-center Phase 1/2 clinical trial evaluating PBFT02 in symptomatic FTD-GRN and FTD-C9orf72 patients. As of June 2025, interim data from eight treated patients demonstrated robust and durable increases in cerebrospinal fluid progranulin levels and early evidence of reduced disease progression biomarkers compared to natural history expectations.
Beyond PBFT02, Passage Bio maintains an active preclinical research program through a collaboration agreement with Gemma Biotherapeutics to develop genetic medicines for Huntington's disease, with a clinical candidate expected in the second half of 2026. The company previously advanced three pediatric programs to clinical stage, which have been outlicensed to Gemma through sublicense agreements.
Passage Bio's approach emphasizes rigorous capsid and transgene selection, optimal route of administration, cross-correction mechanisms, and effective use of biomarkers to maximize the probability of technical and regulatory success. The company manufactures clinical supply through third-party partners, including Catalent, and has received Orphan Drug Designation from the FDA for PBFT02 in FTD-GRN.
Company details
- Sector
- Healthcare
- Industry
- Biological Products
- Headquarters
- PHILADELPHIA, PA
- Fiscal year end
- December
- CIK
- 1787297
- SIC
- 2836
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Passage BIO, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Passage BIO, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Passage BIO, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Passage BIO, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Passage BIO, Inc.'s last four quarterly filings that the numbers alone won't show?”